We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 31% in a year while the S&P 500 rose 12%.
| Outperforming | Up 57% in 6 months vs the S&P's +2% |
| Latest filing | 8-K, Oct 27 |
After its last 4 reports it closed +3.0% on average, higher 2 of 4 times.
Excellentfor quality, not price, 7 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. IQV scores 17 today, against a median of 13 over its last 20 recorded sessions.
IQV is #13 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 13 |
Net income over four quarters: IQV $1.39B, MEDP $518M, ICLR $449M, CRL $40.2M.
Expected to report Thu Feb 11, before the open (in 93 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $4.4B, 8% more than a year ago; a profit of $2.10 a share, from $1.93.
| Line | Q3 2026 | Q3 2025 |
|---|---|---|
| Research and Development Solutions | $2.6B | $2.4B |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 27)
| Measure | Figure |
|---|---|
| Revenue | $17.35B to $17.50B |
Sales grew 7.5% a year over 5 years, fiscal 2020 to 2025.
Its share count fell 2.3% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 27, 2026 | -2.2% | -0.8% | -5.5% |
| Jul 28, 2026 | +10.2% | +13.9% | +9.4% |
| May 5, 2026 | -0.7% | +9.6% | +7.8% |
Sales grew every year from 2018 to 2025, to $16B. It made a profit in each of the eight years.
RSI 56.0, MACD above signal, above both averages. Not scored.
6 insiders sold $29.9M across 9 filings in the last 6 months. No open-market buys on record. The newest:
15 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: IQV is 0.2% of SCHG, under 0.1% of SPYI, and under 0.1% of IVV, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
“Our Technology & Analytics Solutions business competes with a broad and diverse set of businesses.”
IQV scores 17 today, which Breakaway calls Excellent. It is #13 of 281 in Biotech by Quality Score, with 7 of 14 chart checks firing. Up 31% in a year while the S&P 500 rose 12%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
IQV scores 17 today, which Breakaway calls Excellent (15 to 19). That is #13 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IQV's 17.
6 insiders sold $29.9M across 9 filings in the last 6 months. No open-market buys on record. The newest is James G. Berkshire, Insider, who sold $697K on Sep 2. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.